MS and Demyelinating Disorders

November news includes potential Alzheimer treatments, FDA approval of a device to prevent recurrent stroke, & a newly typified headache disorder.

Studies include a potential test for MS, a link between headaches and hypothyroidism, and a risk prediction scale for stroke patients.

Data blitz presentations at ANA 2016 featured studies on neuronal dysfunction and degeneration in ALS, Parkinson disease, transverse myelitis, & more.

Award-winning posters presented during the American Neurological Association Annual Meeting discussed risks in stroke, MS, and migraine.

Oct. news includes an approved deep brain stimulation system for movement disorders & biomarkers that improve risk assessment in atrial fibrillation.

Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

This ECTRIMS session includes studies using 7T and 3T MRI images and translocator protein PET scans, as well as phenotypes in gray matter and more.

Research presented at this ECTRIMS session covered management of multiple sclerosis-related fatigue, cognitive issues, and gait impairment.

Hot Topics session at ECTRIMS 2016: treat early active RRMS with potent induction therapy or immunomodulation then escalation? Where do you stand?

The session featured a study comparing MRI criteria for diagnosing MS, the role of spinal cord volume loss in predicting disease activity, and more.

New research covers treating MS early, identifying those at risk for AED-induced psychosis, & selecting a drug for epilepsy patients with migraines.

Our August news includes a potential classification system for Alzheimer disease, new findings in a 3D model of TBI, and migraine treatments.

Our July news includes the Alzheimer-diabetes link, increased rates of Parkinson, and guidelines for acute migraine treatment in the ED.

How do you approach the management of patients with multiple sclerosis and another autoimmune condition, such as psoriasis?

Our May news includes memory replay disruption in Alzheimer disease, impulse control disorder in Parkinson disease, and return to play in TBI.

From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.

Interactive case study discussions highlighted the issue that treating multiple sclerosis often involves swimming murky waters.

Three new studies on multiple sclerosis discuss potential ways to prevent the development of cognitive problems, or the development of the disease.

By studying first-degree relatives of patients with MS, can researchers perfect a risk algorithm for the disease?

Researchers investigated a possible quantitative measure of taste function that correlated with myelin-related lesions found in MS patients.

Risk factors regarding MS, including genetic research findings and progressive multifocal leukoencephalopathy while taking natalizumab, are discussed.

Our Feb. news & research include two new migraine drugs, the stroke-Parkinson link, and the potential of an anticancer drug to prevent Alzheimer.

Neuropsychological deficits often remain undiscovered during routine clinical examinations of multiple sclerosis patients due to time constraints.

Our Jan. news & research list includes the possible lingering effects of childhood concussion and the benefits of vitamin D for MS.